Skip to main content
Figure 2 | BMC Palliative Care

Figure 2

From: An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain

Figure 2

BPI pain relief: summary from baseline to subsequent months and end point (overall and by previous treatment). Baseline and months 1 to 12 = absolute values; end point = last observation carried forward. Participating patient numbers - OROS® hydromorphone: n = 32 at baseline, n = 4 at month 12, and n = 33 at end point; CR morphine: n = 32 at baseline, n = 6 at month 12, and n = 33 at end point; overall: n = 64 at baseline, n = 10 at month 12, and n = 66 at end point. BPI, brief pain inventory; CR, controlled-release; SE, standard error.

Back to article page

BMC Palliative Care

ISSN: 1472-684X

Contact us